Morten Tulstrup
Overview
Explore the profile of Morten Tulstrup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bliddal S, Banasik K, Pedersen O, Nissen J, Cantwell L, Schwinn M, et al.
Sci Rep
. 2021 Jun;
11(1):13153.
PMID: 34162913
Reports of persistent symptoms after hospitalization with COVID-19 have raised concern of a "long COVID" syndrome. This study aimed at determining the prevalence of and risk factors for acute and...
12.
Jiang C, Yang W, Moriyama T, Liu C, Smith C, Yang W, et al.
Clin Pharmacol Ther
. 2020 Oct;
109(6):1538-1545.
PMID: 33124053
6-mercaptopurine (6-MP) is widely used in the treatment of acute lymphoblastic leukemia (ALL), and its cytotoxicity is primarily mediated by thioguanine nucleotide (TGN) metabolites. A recent genomewide association study has...
13.
Brunsvig Jarvis K, Nielsen R, Gupta R, Dahl Hede F, Huttunen P, Jonsson O, et al.
Thromb Res
. 2020 Aug;
196:15-20.
PMID: 32818716
Introduction: Thromboembolism (TE) is a common and serious toxicity of acute lymphoblastic leukemia (ALL) treatment, but studies of genetic predisposition have been underpowered with conflicting results. We tested whether TE...
14.
Mateos M, Tulstrup M, Quinn M, Tuckuviene R, Marshall G, Gupta R, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32438682
Methods: We undertook a genome-wide association study (GWAS) meta-analysis for VTE in consecutively treated children in the Nordic/Baltic acute lymphoblastic leukemia 2008 (ALL2008) cohort and the Australian Evaluation of Risk...
15.
Tulstrup M, Moriyama T, Jiang C, Grosjean M, Nersting J, Abrahamsson J, et al.
Blood
. 2020 May;
136(10):1161-1168.
PMID: 32391884
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To...
16.
Brunsvig Jarvis K, LeBlanc M, Tulstrup M, Nielsen R, Albertsen B, Gupta R, et al.
Thromb Res
. 2019 Nov;
184:92-98.
PMID: 31715544
Introduction: Thromboembolism is a serious toxicity of acute lymphoblastic leukemia treatment, and contributes to substantial morbidity and mortality. Several single nucleotide polymorphisms have been associated with thromboembolism in the general...
17.
Wolthers B, Frandsen T, Patel C, Abaji R, Attarbaschi A, Barzilai S, et al.
Haematologica
. 2018 Nov;
104(3):556-563.
PMID: 30467200
Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0-17.9...
18.
Hojfeldt S, Wolthers B, Tulstrup M, Abrahamsson J, Gupta R, Harila-Saari A, et al.
Br J Haematol
. 2018 Nov;
184(3):405-417.
PMID: 30450575
Asparaginase is essential in childhood acute lymphoblastic leukaemia (ALL) treatment, however hypersensitivity reactions to pegylated asparaginase (PEG-asparaginase) hampers anti-neoplastic efficacy. Patients with PEG-asparaginase hypersensitivity have been shown to possess zero...
19.
Tulstrup M, Grosjean M, Nygaard Nielsen S, Grell K, Wolthers B, Wegener P, et al.
Leukemia
. 2018 Sep;
32(12):2527-2535.
PMID: 30201983
The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means...
20.
Tulstrup M, Frandsen T, Abrahamsson J, Lund B, Vettenranta K, Jonsson O, et al.
Eur J Haematol
. 2017 Oct;
100(1):53-60.
PMID: 28983968
Objectives: This randomized controlled trial tested the hypothesis that children with non-high-risk acute lymphoblastic leukemia could benefit from individualized 6-mercaptopurine increments during consolidation therapy (NCT00816049). Primary and secondary end points...